Table 2.

In vitro cytotoxicity of IMGN779 against primary AML progenitor cells

Sample #IC50 (pmol/L)CD33 expression (LP)MutationsP-glycoprotein activity
431010,881FLT3-ITD, NPM12.1
50118,572FLT3-ITD2.5
10166,893Negative1.0
82212,567ND1.1
47261,084Negative1.6
172711,191FLT3-ITD1.1
56288,101NPM11.9
5298,508FLT3-ITD0.3
53357,676FLT3-ITD, NPM11.6
463815,988FLT3-ITD1.8
654810,211CEPBα2.0
29636,922FLT3-ITD, NPM11.5
118715,574FLT3-ITD, NPM10.8
33891,739NPM11.9
27918,442FLT3-ITD, NPM11.2
451073,312c-KIT1.1
581108,759NPM11.6
151122,193ND1.2
2412411,269Negative1.2
39139954FLT3-ITD, NPM1, CEPBα2.8
5213913,956FLT3-ITD, NPM11.1
6314411,961negative2.3
61a15811,141FLT3-ITD, NPM11.5
481953,356FLT3-ITD1.6
352066,932FLT3-ITD, NPM11.2
5520711,701FLT3-ITD, NPM11.3
19214983Negative1.3
132181,251FLT3-ITD1.3
572277,809FLT3-ITD1.3
422683,599FLT3-ITD2.3
362853,136FLT3-ITD1.8
322904,831Negative2.6
283024,633FLT3-ITD, NPM11.6
383812,034Negative2.4
64041,237ND1.2
164803,893ND2.2
645813,184NPM11.8
1583554Negative1.9
686474,812CEPBα5.0
207353,767FLT3-ITD, NPM11.0
379122,405JAK22.2
79291,330ND1.8
341,196903Negative2.2
121,2341,040Negative1.6
211,3572,183Negative1.6
401,453213Negative2.3
221,4793,384ND2.2
541,6683,796FLT3-ITD1.9
60a2,0067,599FLT3-ITD, NPM11.4
62a2,0955,597Negative3.1
  • aSamples 60, 61, and 62 are from relapsed (60) and refractory patients (61, 62). All others were obtained at the time of diagnosis.